Sodium-myo-inositol co-transporter (SMIT-1) mRNA is increased in neutrophils of patients with bipolar I disorder and down-regulated under treatment with mood stabilizers

International Journal of Neuropsychopharmacology

Volumn 10, Issue 1, 2007, Pages 63-71

  Willmroth, Frank ^a   Drieling, Tobias ^a   Lamla, Ulrich ^a   Marcushen, Michael ^a   Wark, Hans Jörg ^a   Van Calker, Dietrich ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Endophenotype; Inositol; Lithium; Manic depressive illness; Signal transduction; Valproate

Indexed keywords

COTRANSPORTER; INOSITOL; LITHIUM SALT; MESSENGER RNA; MOOD STABILIZER; VALPROIC ACID;

ADULT; AGED; ARTICLE; BIPOLAR I DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; IN VIVO STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTIMANIC AGENTS; BIPOLAR DISORDER; CASE-CONTROL STUDIES; DOWN-REGULATION; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; LITHIUM COMPOUNDS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEUTROPHILS; PSYCHIATRIC STATUS RATING SCALES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SYMPORTERS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 33846310022     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705006371     Document Type: Article

References (41)

1. Baron M (2002). Manic-depression genes and the new millennium: poised for discovery. Molecular Psychiatry 7, 342-358.
2. Berridge MJ, Downes CP, Hanley MR (1989). Neural and developmental actions of lithium: a unifying hypothesis. Cell 59, 411-419.
3. Berry GT, Buccafusca R, Greer JJ, Eccleston E (2004). Phosphoinositide deficiency due to inositol depletion is not a mechanism of lithium action in brain. Molecular Genetics and Metabolism 82, 87-92.
4. +/myo-inositol cotransporter gene (SLC5A3): molecular cloning and localization to chromosome 21. Genomics 25, 507-513.
5. Berry GT, Wang ZJ, Dreha SF, Finucane BM, Zimmerman RA (1999). In vivo brain myo-inositol levels in children with Down syndrome. Journal of Pediatrics 135, 94-97.
6. +/myo-inositol cotransporter leads to brain myo-inositol depletion and central apnea. Journal of Biological Chemistry 278, 18297-18302.
7. Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G (2001). Lithium for maintenance treatment of mood disorders. Cochrane Database of Systematic Reviews (3): CD003013.
8. Cairns V, von Zerssen D, Stutte KH, Mombour W (1982). The stability of the symptom groupings in the Inpatient Multidimensional Psychiatric Scale (IMPS). Journal of Psychiatric Research 17, 19-28.
9. Cecil KM, DelBello MP, Sellars MC, Strakowski SM (2003). Proton magnetic resonance spectroscopy of the frontal lobe and cerebellar vermis in children with a mood disorder and a familial risk for bipolar disorders. Journal of Child and Adolescent Psychopharmacology 13, 545-555.
10. Chau JF, Lee MK, Law JW, Chung SK, Chung SS (2005). Sodium/myo-inositol cotransporter-1 is essential for the development and function of the peripheral nerves. FASEB Journal 19, 1887-1889.
11. Dager SR, Friedman SD, Parow A, Demopulos C, Stoll AL, Lyoo IK, Dunner DL, Renshaw PF (2004). Brain metabolic alterations in medication-free patients with bipolar disorder. Archives of General Psychiatry 61, 450-458.
12. Davanzo P, Thomas MA, Yue K, Oshiro T, Belin T, Strober M, McCracken J (2001). Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology 24, 359-369.
13. Davanzo P, Yue K, Thomas MA, Belin T, Mintz J, Venkatraman TN, Santoro E, Barnett S, McCracken J (2003). Proton magnetic resonance spectroscopy of bipolar disorder versus intermittent explosive disorder in children and adolescents. American Journal of Psychiatry 160, 1442-1452.
14. Evans DL, Charney DS (2003). Mood disorders and medical illness: a major public health problem. Biological Psychiatry 54, 177-180.
15. Friedman SD, Dager SR, Parow A, Hirashima F, Demopulos C, Stoll AL, Lyoo IK, Dunner DL, Renshaw PF (2004). Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biological Psychiatry 56, 340-348.
16. Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK (2004). Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Molecular Psychiatry 9, 734-755.
17. Harwood AJ, Agam G (2003). Search for a common mechanism of mood stabilizers. Biochemical Pharmacology 15, 179-189.
18. Hiller W, v. Zerssen D, Mombour W, Wittchen H-U (1986). Inpatient Multidimensional Psychiatric Scale [Manual]. Weinheim: Beltz Test.
19. Huang W, Alexander GE, Daly EM, Shetty HU, Krasuski JS (1999). Rapoport SI, Schapiro MB. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study. American Journal of Psychiatry 156, 1879-1886.
20. Huang W, Galdzicki Z, van Gelderen P, Balbo A, Chikhale EG, Schapiro MB, Rapoport SI (2000). Brain myo-inositol level is elevated in Ts65Dn mouse and reduced after lithium treatment. Neuroreport 28, 445-448.
21. Keck Jr. PE, Manji HK (2002). Current and emerging treatments for acute mania and long-term prophylaxis for bipolar disorder. In: Davis KL, Charney DS, Coyle JT, Nemeroff CB (Eds.), Neuropsychopharmacology: The Fifth Generation of Progress (pp. 1109-1118). Philadelphia: Lippincott Williams & Wilkins.
22. Lenox RH, Gould TD, Manji HK (2002). Endophenotypes in bipolar disorder. American Journal of Medical Genetics 14, 391-406.
23. Lubrich B, Spleiss O, Gebicke-Haerter PJ, van Calker D (2000). Differential expression, activity and regulation of the sodium/myo-inositol cotransporter in astrocyte cultures from different regions of the rat brain. Neuropharmacology 39, 680-690.
24. Lubrich B, van Calker D (1999). Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Neuropsychopharmacology 21, 519-529.
25. Manji HK, Moore GJ, Chen G (2001). Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers. British Journal of Psychiatry 41 (Suppl.), 107-119.
26. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, Gray NA, Zarate Jr. CA, Charney DS (2003). Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biological Psychiatry 53, 707-742.
27. +)/myo-inositol cotransporter (SLC5A3) gene. Cytogenetics and Cellular Genetics 88, 153-158.
28. Moore GJ, Bebchuk JM, Parrish JK, Faulk MW, Arfken CL, Strahl-Bevacqua J, Manji HK (1999). Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. American Journal of Psychiatry 156, 1902-1908.
29. Murray CJL, Lopez AD (1996). The Global Burden of Disease Summary. Cambridge, MA: Harvard School of Public Health.
30. O'Donnell T, Rotzinger S, Nakashima TT, Hanstock CC, Ulrich M, Silverstone PH (2003). Chronic lithium and sodium valproate both decrease the concentration of myoinositol and increase the concentration of inositol monophosphates in rat brain. European Neuropsychopharmacology 13, 199-207.
31. Shaltiel G, Shamir A, Shapiro J, Ding D, Dalton E, Bialer M, Harwood AJ, Belmaker RH, Greenberg ML, Agam G (2004). Valproate decreases inositol biosynthesis. Biological Psychiatry 56, 868-874.
32. Shetty HU, Schapiro MB, Holloway HW, Rapoport SI (1995). Polyol profiles in Down syndrome: myo-inositol, specifically, is elevated in the cerebrospinal fluid. Journal of Clinical Investigation 95, 542-546.
33. Shetty HU, Siarey RJ, Galdzicki Z, Stoll J, Rapoport SI (2000). Ts65Dn mouse, a Down syndrome model, exhibits elevated myo-inositol in selected brain regions and peripheral tissues. Neurochemical Research 25, 431-435.
34. Silverstone PH, Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC (2002). Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients. Human Psychopharmacology 17, 321-327.
35. Simon GE (2003). Social and economic burden of mood disorders. Biological Psychiatry 54, 208-215.
36. Solomon DA, Keitner GI, Miller IW, Shea MT, Keller MB (1995). Course of illness and maintenance treatments for patients with bipolar disorder. Journal of Clinical Psychiatry 56, 5-13.
37. van Calker D, Belmaker RH (2000). The high affinity inositol transport system-implications for the pathophysiology and treatment of bipolar disorder. Bipolar Disorders 2, 102-107.
38. von Zerssen D (1976). Die Befindlichkeits-Skala. Weinheim: Beltz-Test.
39. Williams RS, Cheng L, Mudge AW, Harwood AJ (2002). A common mechanism of action for three mood-stabilizing drugs. Nature 417, 292-295.
40. Wittchen H-U, Wunderlich U, Gruschwitz S, Zaudig M (1997) SKID-I. Strukturiertes Klinisches Interview für DSM-IV. Achse I: Psychische Störungen. Göttingen, Bern, Toronto, Seattle: Hogrefe.
41. Wolfson M, Bersudsky Y, Zinger E, Simkin M, Belmaker RH, Hertz L (2000). Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations. Brain Research 855, 158-161.